Department of Biological and Environmental Science and NanoScience Center, University of Jyväskylä, Jyväskylä, Finland.
J Virol. 2014 May;88(9):5138-51. doi: 10.1128/JVI.03275-13. Epub 2014 Feb 26.
Coxsackievirus A9 (CVA9) is a member of the human enterovirus B species in the Enterovirus genus of the family Picornaviridae. According to earlier studies, CVA9 binds to αVβ3 and αVβ6 integrins on the cell surface and utilizes β2-microglobulin, dynamin, and Arf6 for internalization. However, the structures utilized by the virus for internalization and uncoating are less well understood. We show here, based on electron microscopy, that CVA9 is found in multivesicular structures 2 h postinfection (p.i.). A neutral red labeling assay revealed that uncoating occurs mainly around 2 h p.i., while double-stranded RNA is found in the cytoplasm after 3 h p.i. The biogenesis of multivesicular bodies (MVBs) is crucial for promoting infection, as judged by the strong inhibitory effect of the wild-type form of Hrs and dominant negative form of VPS4 in CVA9 infection. CVA9 infection is dependent on phospholipase C at the start of infection, whereas Rac1 is especially important between 1 and 3 h p.i., when the virus is in endosomes. Several lines of evidence implicate that low pH does not play a role in CVA9 infection. The infection is not affected by Bafilomycin A1. In addition, CVA9 is not targeted to acidic late endosomes or lysosomes, and the MVBs accumulating CVA9 have a neutral pH. Thus, CVA9 is the second enterovirus demonstrated so far, after echovirus 1, that can trigger neutral MVBs, which are important for virus infection.
We demonstrate here that the enterovirus coxsackievirus A9 (CVA9) uses a nonclathrin and nonacidic pathway to infect cells. CVA9 does not accumulate in conventional late endosomes or lysosomes. We found that inhibitors of phospholipase C (PLC), Rac1, and the Na(+)/H(+) exchanger decreased CVA9 infection. The PLC inhibitor acts on early entry, the Rac1 inhibitor acts between 1 and 3 h, when the virus is in endosomes, and the Na(+)/H(+) exchange inhibitor acts during various steps during the virus life cycle. The infection depends on the formation of novel neutral multivesicular bodies (MVBs), which accumulate CVA9 during the first hours of entry. Thus, CVA9 is the second enterovirus demonstrated so far, after echovirus 1, that can trigger formation of neutral MVBs. The data show that these enteroviruses favor nonacidic conditions and complex MVBs to promote virus infection.
柯萨奇病毒 A9(CVA9)是小核糖核酸病毒科肠道病毒属人肠道病毒 B 种的一个成员。根据早期的研究,CVA9 结合到细胞表面的 αVβ3 和 αVβ6 整联蛋白上,并利用β2-微球蛋白、动力蛋白和 Arf6 进行内化。然而,病毒用于内化和脱壳的结构不太清楚。我们在这里通过电子显微镜显示,CVA9 在感染后 2 小时内可在多泡体中被发现。中性红标记测定显示脱壳主要发生在感染后 2 小时左右,而双链 RNA 在感染后 3 小时出现在细胞质中。多泡体(MVBs)的生物发生对于促进感染至关重要,这可以从野生型 Hrs 和显性失活形式的 VPS4 在 CVA9 感染中的强烈抑制作用来判断。CVA9 感染依赖于感染开始时的磷脂酶 C,而 Rac1 在 1 至 3 小时之间尤其重要,此时病毒在内涵体中。有几条证据表明低 pH 值在 CVA9 感染中不起作用。Bafilomycin A1 不影响感染。此外,CVA9 不靶向酸性晚期内体或溶酶体,并且积累 CVA9 的 MVBs 呈中性 pH 值。因此,CVA9 是迄今为止继肠道病毒 1 之后第二个被证实可触发中性 MVBs 的肠道病毒,这对病毒感染很重要。
我们在这里证明,肠道病毒柯萨奇病毒 A9(CVA9)使用非网格蛋白和非酸性途径感染细胞。CVA9 不会在常规晚期内体或溶酶体中积累。我们发现,磷脂酶 C(PLC)、Rac1 和 Na(+)/H(+) 交换抑制剂的抑制剂降低了 CVA9 的感染。PLC 抑制剂在早期进入时起作用,Rac1 抑制剂在 1 至 3 小时之间起作用,此时病毒在内体中,Na(+)/H(+) 交换抑制剂在病毒生命周期的各个阶段起作用。感染依赖于新型中性多泡体(MVBs)的形成,这些 MVBs 在进入的头几个小时内积累 CVA9。因此,CVA9 是迄今为止继肠道病毒 1 之后第二个被证实可触发中性 MVBs 的肠道病毒。数据表明,这些肠道病毒有利于非酸性条件和复杂的 MVBs 以促进病毒感染。